Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novavax, Inc. - Common Stock (NQ: NVAX )

8.190 +0.010 (+0.12%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novavax, Inc. - Common Stock

< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
61 62 Next >
Novavax Stock Up on Swiss Approval of Nuvaxovid
Novavax’s Covid-19 vaccine Nuvaxovid just got approved for in Switzerland. NVAX stock is up on news. It couldn’t have come at a better time. 
Via InvestorPlace
Novavax's COVID-19 Vaccine Approved In Switzerland
Via Benzinga
Novavax Stock Is Slumping: Why Buy the Dip?
Novavax lost nearly one-fifth of its value in the last week and risks further selling pressure, despite offering an mRNA alternative. 
Via InvestorPlace
Novavax Stock Is Tanking Despite New Covid-19 Vaccine Authorization
NVAX stock isn't a darling on Wall Street right now, but a rally could be just around the corner as Novavax pursues its global ambitions. 
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Vaccine Makers Down on FDA Meeting, Novavax Most at Risk
The major covid-19 vaccine makers are all down, anticipating bad-for-business news from the FDA. However, NVAX stock has the most to lose. 
Via InvestorPlace
Why Is Novavax (NVAX) Stock Down Today?
Today, investors in Novavax and NVAX stock appear to be spooked by some key rhetoric from Dr. Anthony Fauci regarding vaccinations. 
Via InvestorPlace
The Waiting Game Is Wearing Thin for Novavax Investors
If you’re not otherwise engaged with NVAX stock, it’s best to wait until the picture gets clearer on EUA approval. 
Via InvestorPlace
Dear Biotech Investors: Novavax’s Comparable Vaccine Matters
Researchers compared Novavax’s vaccine to three others on the market, offering a thorough glimpse of protection from boosters. 
Via InvestorPlace
FDA Official Says Frequent COVID-19 Booster Shows Not Sustainable: WSJ
According to a U.S. health regulator, asking people to get COVID-19 boosters frequently wasn't sustainable because of vaccine fatigue, and authorities needed to develop a long-term strategy for... 
Via Benzinga
Is NVAX Stock a Buy at 52-Week Low? Skip the Novavax Portfolio Injection
NVAX stock could slide even further as research & development requirements stack up against its balance sheet's capacity. 
Via InvestorPlace
Novavax Just Hit A New Yearly Low, Here’s How To Buy It Even Lower
NVAX stock is still falling. Get paid for your patience to be a buyer at lower levels by selling expensive puts. 
Via InvestorPlace
Don’t Bet on New Highs for Novavax Stock
Investors would do well to avoid repeating the mistake of expecting moonshots in NVAX stock. The business may do better, but the stock won't. 
Via InvestorPlace
4 Top Stock Trades for Wednesday: Dogecoin, NVDA, TLRY, NVAX
Dogecoin, Nvidia, Tilray and Novavax were our top stock trades for Wednesday. Here's how the charts are setting up now. 
Via InvestorPlace
What's Going On With Novavax Shares Today?
Novavax Inc (NASDAQ: NVAX) shares are trading significantly lower Tuesday. According to data from Benzinga Pro, Tuesday's trading volume is in line with Novavax's average trading volume over a 100-day... 
Via Benzinga
Novavax Has More Upside Ahead, as Covid-19 Shots Hit the Market
After Covid-19 vaccine delivery and regulatory woes, there is finally more upside than downside risks with NVAX stock. 
Via InvestorPlace
What to Make of Novavax’s Adolescent Covid-19 Vaccine Move
NVAX stock foray in the adolescent Covid-19 vaccine market could pay dividends but investors should tread with caution at this time. 
Via InvestorPlace
Novavax’s First Canadian Shipments Are Boosting NVAX Stock
Novavax delivered its first shipments to Canadian health authorities last week, and the news continues to help NVAX stock climb higher today. 
Via InvestorPlace
Novavax Stock Is Alluringly Attractive at This Stage
Novavax is close to securing FDA approval for its Covid-19 vaccine, yet NVAX stock is down since the end of January. What gives? 
Via InvestorPlace
10 Investor Questions About COVID-19, Answered
The COVID-19 outbreak has finally subsided in the U.S., but biotech investors still have plenty of lingering questions about the virus and what to expect in the months and years ahead. On Thursday,... 
Via Benzinga
How to Approach Trading Downtrodden Novavax Today
There are obvious reasons to be bearish on NVAX stock's price chart, but a word to the wise would include the use of this type of put spread. 
Via InvestorPlace
Mitt Romney Says Senators Reached Tentative $10B Deal In Additional COVID-19 Relief Funding: CNBC
Via Benzinga
The Daily Biotech Pulse: Amylyx Announces Negative Adcom Vote, Clovis Jumps On Ovarian Cancer Data, Masimo Warns Of Q1 Shortfall
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Omicron More Severe For Unvaccinated Children Than Other Strains, Hong Kong Study Finds: Bloomberg
According to a Hong Kong-based study, the omicron variant of COVID-19 has been linked to more hospitalizations, severe complicat 
Via Benzinga
If You Invested $1000 In Novavax 5 Years Ago, Here's How Much You Would Have Today
Novavax (NASDAQ:NVAX) has outperformed the market over the past 5 years by 12.42% on an annualized basis producing an average annual return of 26.64%. Currently, Novavax has a market capitalization of... 
Via Benzinga
EMA Starts Review Of Sanofi-GlaxoSmithKline's COVID-19 Vaccine
Via Benzinga
Novavax Stock Is a Bet on Interest From Unvaccinated People
NVAX stock represents a vaccine that lacks approval. There is real appeal behind the narrative, as it may appeal to unvaccinated people. 
Via InvestorPlace
Biden Administration Proposes $82B In Spending For Future Pandemics Preparedness
President Biden's budget proposal calls for $81.7 billion to spend over five years preparing for future pandemics, which would be a significant investment in boosting the country 
Via Benzinga
Looking At Novavax's Recent Whale Trades
Someone with a lot of money to spend has taken a bullish stance on Novavax (NASDAQ:NVAX). And retail traders should know. We noticed this today when the big position showed up on publicly available... 
Via Benzinga
Why Most Kids Did Not Suffer Badly Due To COVID-19 Infection? Scientists Look To Solve Mystery: CNBC
The COVID-19 pandemic has led to over 6 million fatalities. The scientists are still studying why most children do not suffer badly from coronavirus infection. 
Via Benzinga
< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
61 62 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.